



Biochemical markers for clinical monitoring of tissue perfusion

Marek Janotka¹ · Petr Ostadal¹

Received: 23 September 2020 / Accepted: 9 December 2020 / Published online: 2 January 2021
© The Author(s) 2021

Abstract

The assessment and monitoring of the tissue perfusion is extremely important in critical conditions involving circulatory shock. There is a wide range of established methods for the assessment of cardiac output as a surrogate of oxygen delivery to the peripheral tissues. However, the evaluation of whether particular oxygen delivery is sufficient to ensure cellular metabolic demands is more challenging. In recent years, specific biochemical parameters have been described to indicate the status between tissue oxygen demands and supply. In this review, the authors summarize the application of some of these biochemical markers, including mixed venous oxygen saturation (S_vO_2), lactate, central venous–arterial carbon dioxide difference (PCO_2 gap), and PCO_2 gap/central arterial-to-venous oxygen difference ($C_{a-v}O_2$) for hemodynamic assessment of tissue perfusion. The thorough monitoring of the adequacy of tissue perfusion and oxygen supply in critical conditions is essential for the selection of the most appropriate therapeutic strategy and it is associated with improved clinical outcomes.

Keywords Microcirculation · Circulatory shock · Tissue perfusion · Hemodynamic monitoring · Oxygen saturation · Lactate

Abbreviations

ΔPCO_2	Venous–arterial carbon dioxide difference from central venous blood
C_aO_2	Arterial oxygen concentration
$C_{a-v}O_2$	Arterial–venous difference in oxygen concentration
CO	Cardiac output
CVC	Central venous catheter
C_vO_2	Venous oxygen concentration
DO_2	Oxygen delivery
EO_2	Oxygen extraction
GDT	Goal-directed therapy
HGB	Hemoglobin
HR	Heart rate
NIRS	Near-infrared spectroscopy
PAC	Pulmonary artery catheter
P_aCO_2	Partial pressure of arterial carbon dioxide
P_aO_2	Partial pressure of arterial oxygen
PCO_2 gap	Venous–arterial carbon dioxide difference
$P_{cv}CO_2$	Partial pressure of central venous carbon dioxide

PDH	Pyruvate dehydrogenase
$P_{v-a}CO_2$	Venous–arterial carbon dioxide partial pressure difference
P_vCO_2	Partial pressure of mixed venous carbon dioxide
RQ	Respiratory quotient
rSO_2	Peripheral oxygen saturation
S_aO_2	Arterial oxygen saturation
$S_{cv}O_2$	Central venous oxygen saturation
SV	Stroke volume
S_vO_2	Mixed venous oxygen saturation
VCO_2	Carbon dioxide production
VO_2	Oxygen consumption

Introduction

In individuals experiencing circulatory shock, it is essential to know whether cardiac output (CO) is sufficient to address tissue demands. Regardless of the type of shock, however, the ultimate consequences remain unchanged and have the same definition: a failure of oxygen (O_2) utilization and cell metabolism caused by hypoperfusion resulting from circulatory failure—either the macrocirculation (heart and great vessels) or the microcirculation (capillaries, blood elements, cells) [1]. Hypoperfusion can be defined as a supply of O_2

✉ Petr Ostadal
ostadal.petr@gmail.com

¹ Cardiovascular Center, Na Homolce Hospital, 15000 Prague, Czech Republic

that does not adequately address the needs of cells [2, 3]. Failure of O_2 use leads to anaerobic metabolism which is the source of several detectable products and byproducts. There is a broad spectrum of methods (from non-invasive to invasive) for measuring O_2 supply for which CO is usually used as a surrogate in clinical practice [4] (Fig. 1).

However, it is difficult to measure O_2 consumption because it can be estimated from nomograms or measured directly using exhaled gases; regardless, however, neither method is suitable for routine clinical use [5].

In treating any type of circulatory shock, sufficient CO must be ensured to fulfill tissue demands. CO is determined by heart rate (HR) and stroke volume (SV), according to the following equation:

$$CO = HR \times SV$$

SV depends on preload, afterload, and contractility. In clinical practice, two approaches are used to increase SV (and CO): adding volume (to increase preload based on the Frank–Starling law) and administering agents with a positive inotropic effect (i.e., inotropes) to increase cardiac contractility. However, it is well known from clinical trials that the administration of higher doses of both volume and/or inotropes is associated with worse outcomes [6–9]. There is no rigorous threshold of CO that should be reached in treating circulatory shock, and the goal is to increase CO only as much as needed to ensure adequate perfusion [1]. The adequacy of perfusion (or hypoperfusion) is difficult to assess in clinical practice. Instrumental methods examining the microcirculation (e.g., videomicroscopic techniques) are not well established for clinical use [10]. Clinical signs of

hypoperfusion are not very sensitive and manifest only in the later stages of shock [11]. Currently, the easiest way to assess the adequacy of perfusion and relationship between O_2 supply and demand(s) is, therefore, the measurement of biochemical markers related to O_2 metabolism (Fig. 1). However, the interpretation of the measured values requires understanding of the complex physiological principles in the context of other hemodynamic findings. The aim of our review was, therefore, to summarize current possibilities of the assessment and monitoring of tissue perfusion adequacy and interpretation of the values in different critical circulatory situations. The most frequently used parameters in clinical practice include mixed venous oxygen saturation (S_vO_2), lactate levels, partial pressure of carbon dioxide (PCO_2) gap, and surrogates of the respiratory quotient (RQ). Evidence supporting the use of these parameters in individuals who experience septic shock is quite robust; however, they are also applicable to those who experience cardiogenic shock [2, 3]. Although sex and age may affect the course of shock (e.g., different immune response), it seems that these factors do not influence the clinical use of the parameters of tissue perfusion adequacy [12, 13].

Global oxygen metabolism

Oxygen delivery (DO_2) is expressed by the equation:

$$DO_2 = CO \times \text{arterial } O_2 \text{ concentration}$$

The major part of O_2 in the blood is carried by hemoglobin (HGB). Only a clinically insignificant amount of O_2 is physically dissolved and, therefore, is usually omitted:

$$DO_2 = CO \times (\text{concentration } O_2 \text{ bound to HGB} + \text{concentration } O_2 \text{ dissolved}),$$

Fig. 1 Complexity of the evaluation of global circulatory status. DO_2 , oxygen delivery; VO_2 , oxygen consumption; NIRS, near-infrared spectroscopy oximetry; PCO_2 gap, central venous–arterial carbon dioxide difference; S_vO_2 , mixed venous oxygen saturation

- Invasive- pulmonary thermodilution
- Semiinvasive- transpulmonary thermodilution, or chemodilution
 - pulse contour analysis
- Noninvasive- echography
 - bioimpedance, plethysmography
 - capnography
- Direct measurement of exhaled gas
- Estimate with equations and nomograms

DELIVERY O_2 (DO_2) **CONSUMPTION O_2 (VO_2)**

- Lactate
 - S_vO_2
 - pCO_2 gap
 - $p(v-a)CO_2/C(a-v)O_2$
 - NIRS
- } **Blood gas analysis**

$$DO_2 = CO \times (1.38 \times HGB \times S_aO_2 + 0.0031 \times P_aO_2),$$

$$DO_2 = CO \times 1.38 \times HGB \times S_aO_2,$$

where S_aO_2 is the saturation of HGB, P_aO_2 is the partial pressure of arterial oxygen, 1.38 represents the ml of oxygen bound to 1 g of HGB, and 0.0031 is the solubility coefficient of oxygen in plasma [14].

O_2 consumption (VO_2) can be calculated using the Fick principle (uptake of substance by an organ is proportional to the flow to the organ and arteriovenous concentration difference of the substance):

$$VO_2 = CO \times (C_aO_2 - C_vO_2),$$

where C_aO_2 and C_vO_2 represent arterial and venous O_2 concentrations, respectively, or

$$VO_2 = CO \times 1.38 \times HGB \times (S_aO_2 - S_vO_2).$$

Under normal physiological conditions, O_2 consumption depends only on the metabolic state (i.e., the higher metabolic rate the higher the O_2 consumption) and is not influenced by DO_2 . This is based on the fact that DO_2 greatly (up to five times) exceeds O_2 consumption and serves as the delivery reserve for the body [15]. Therefore, under physiological conditions, VO_2 is delivery independent and fluctuation in usual DO_2 does not affect O_2 consumption. There are two compensatory mechanisms for maintaining the equilibrium between VO_2 and DO_2 . If O_2 demands become higher, the compensatory increase in delivery will occur by increasing CO (first mechanism). If the increase in CO is not sufficient, then O_2 extraction (EO_2) from HGB ($EO_2 = S_aO_2 - S_vO_2$) will rise (second mechanism). Increasing EO_2 is associated with a decrease in S_vO_2 . EO_2 is approximately 25–30% in healthy resting conditions, and its possible increase provides a delivery reserve [16]:

$$VO_2 = HR \uparrow \times SV \uparrow \times 1.38 \times HGB \times (S_aO_2 - S_vO_2 \downarrow).$$


If the capacity of an organism to increase CO is diminished or compromised (e.g., heart failure), DO_2 can be further raised only by an increase in EO_2 . If this mechanism is also depleted (S_vO_2 decline to 50%), the critical DO_2 (the least CO necessary to fulfill tissue demands) is reached and switched to adverse anaerobic metabolism with lactate production [14]. If both compensatory mechanisms are exhausted, O_2 consumption becomes entirely dependent on DO_2 , and is known as delivery-dependent VO_2 [14] (Fig. 2).

Primary failure of the macrocirculation (i.e., pump [heart] or great vessels [e.g., pulmonary embolism]) is known as cardiogenic shock and is a failure of DO_2 . Primary failure of the microcirculation and cell metabolism is known as distributive shock (e.g., septic shock) and is a failure of EO_2 (Fig. 3). There is a higher level of critical DO_2 in septic shock (dotted line in Fig. 2) due to failure of the microcirculation and cellular O_2 use, which leads to malfunction of EO_2 and a decrease in functional capillary density (heterogeneity of the capillary bed with good and poor perfusion). Therefore, some patients experiencing septic shock may benefit from increasing CO to higher values. However, this increase must be navigated by SvO_2 and other parameters because routine increase to supranormal levels of CO may be associated with worse outcomes [7]. There can also be an uncoupling of the macro- and microcirculation when normalization of the macrocirculation (i.e., CO) does not improve microcirculation and cell metabolism [17–19].

Venous blood oxygen saturation (S_vO_2 , $S_{cv}O_2$)

Saturation of HGB by O_2 in the venous blood can be measured in mixed venous blood (i.e., S_vO_2) in the pulmonary artery using a pulmonary artery catheter (PAC) or in central

Fig. 2 Relationship between levels of the parameters of global oxygen (O_2) metabolism and O_2 delivery (DO_2) or cardiac output (CO). pCO_2 gap, central venous–arterial carbon dioxide difference; S_vO_2 , mixed venous oxygen saturation; VO_2 , oxygen consumption; EO_2 , oxygen extraction






Fig. 3 Difference between oxygen (O_2) delivery at the microcirculation level in physiological conditions and in septic shock. Thrombosis and edema of capillaries and interstitial edema (due to increased permeability) lead to reduction in microcirculation net and prolonging

of diffusion distance for O_2 . Arteriovenous shunts bypass oxygenated blood directly in the veins. Malfunction of oxidative enzymes lead to decrease in O_2 use. Collectively, this induces the failure of O_2 extraction

Table 1 Relationship between mixed venous oxygen saturation (S_vO_2) and adequacy of oxygen (O_2) delivery

S_vO_2	Adequacy of O_2 delivery
> 80%	Low O_2 extraction, low O_2 cell metabolism
65–80%	Normal O_2 delivery → normal O_2 extraction
50–65%	Low O_2 delivery → compensatory increased O_2 extraction
30–50%	Critical O_2 delivery → O_2 extraction depleted Switch to anaerobic metabolism
< 25%	Cell death

$$S_vO_2 \downarrow = S_aO_2 \downarrow - \frac{VO_2 \uparrow}{CO \downarrow \times 1.38 \times HGB \downarrow}$$

Higher S_vO_2 can be also caused by excessive DO_2 or low consumption (e.g., sedation, myorelaxation, therapeutic hypothermia); however, it is rarely encountered and, therefore, high S_vO_2 is always an alert for EO_2 or O_2 metabolism failure. The possibility of cardiac disease with left-to-right shunt must also be excluded [14].

venous blood ($S_{cv}O_2$) using a central venous catheter (CVC) placed in the internal jugular vein or subclavian vein [20].

Physiological principles


Generally, S_vO_2 values change with DO_2 and EO_2 . S_vO_2 changes with DO_2 (and CO) are non-linear (Fig. 2). There are only small changes in the independency zone from $S_vO_2 > 70\%$ (where compensation occurs through an increase in CO) and in dependency zone from $S_vO_2 < 40\%$ (where compensation through O_2 extraction is depleted). The shape of the curve describing the relationship between S_vO_2 and DO_2 is S-shaped and reflects the dissociation curve of oxy-HGB [20].

Normally, S_vO_2 values range from 65 to 80%. Generally, lower values imply low DO_2 and a higher value means lower EO_2 (Table 1). There are, however, more factors that lower S_vO_2 aside from low CO, including low HGB (anemia), low S_aO_2 (hypoxia), or high VO_2 (i.e., O_2 consumption). Increased consumption can be due to hyperthermia, shivering (thermogenesis), or cramps (epileptic seizure), increased consumption by breathing muscles while weaning from mechanical ventilation, or by psychomotoric agitation. If HGB concentration, arterial saturation, and consumption are optimized, then S_vO_2 depends solely on CO [21].

Difference between $S_{cv}O_2$ and S_vO_2

S_vO_2 represents the saturation of HGB by oxygen in the mixed venous blood drawn from the pulmonary artery using a PAC, and contains blood from the superior vena cava, inferior vena cava, and coronary sinus. S_vO_2 is, therefore, a marker of global EO_2 in the entire body. However, the insertion of a PAC is an especially invasive procedure with many potential risks. $S_{cv}O_2$ represents the saturation of HGB by O_2 from the CVC, usually from the subclavian or jugular vein, and indicates regional EO_2 from the upper part of the body under physiological conditions higher (due to high O_2 demands of the brain) than in the lower part because of the inflow of highly oxygenated venous blood from the kidneys (renal blood flow is as high as one-quarter of CO). In healthy conditions, $S_{cv}O_2$ is generally 2–7% lower than in the mixed venous blood S_vO_2 containing blood from the kidneys (i.e., $S_{cv}O_2 < S_vO_2$). However, during circulatory shock, the situation is much different. Centralization of the circulation leads to vasoconstriction in the visceral organs, with decreasing perfusion and conserving blood for the brain. For this reason, EO_2 in the lower part of the body is higher than in the upper part, and $S_{cv}O_2$ is higher than S_vO_2 , which contains deoxygenated splanchnic blood ($S_{cv}O_2 > S_vO_2$). The difference increases with the severity of shock and can reach 18% [22, 23] (Fig. 4). There are more variables, such as the position of the CVC ($S_{cv}O_2$ and S_vO_2 become similar when a CVC is placed more distally in the right atrium) or lowering demands of the brain by sedation [24]. Although the

Fig. 4 Explanation of the difference between saturation of hemoglobin by O_2 in central venous blood ($S_{cv}O_2$) and mixed venous oxygen saturation (S_vO_2) under physiological conditions and in circulatory shock



absolute values of $S_{cv}O_2$ and S_vO_2 may differ, their trends are the same, and $S_{cv}O_2$ can be used as surrogate for S_vO_2 to assess perfusion adequacy [15].

Measurement

S_vO_2 can be measured either intermittently from blood samples or continually using special catheters (either a PAC or CVC) equipped with optic sensors (light emitted from the tip of the catheter and reflected light from erythrocytes is measured using spectrophotometry). Although these systems need to be calibrated, they provide comparable values [25, 26].

Clinical applications

Marker of tissue hypoxia (adequacy of CO)

The measurement of S_vO_2 is recommended by guidelines for CO adequacy monitoring [6, 27]. It provides information about hypoxia according to the amount of extracted O_2 . As mentioned above, the correlation between CO and S_vO_2 is worse in distributive shock (i.e., septic shock) due to extraction failure, and high S_vO_2 does not exclude low DO_2 . However, even in those states, if S_vO_2 is low, it means DO_2 is low [1].

Prognostic markers and goal-directed therapy

Patients who experience septic shock have a worse prognosis when S_vO_2 is either low (< 65%) or high (> 80%) [6]. Until recently, S_vO_2 was recommended as a parameter for guiding the resuscitation of circulation in the early stage(s) of septic shock based on evidence of mortality reduction (guidelines

from 2012 stated a goal of $S_vO_2 > 65\%$ and $S_{cv}O_2 > 70\%$) [28]. The recommendations changed in 2016 after publication of three clinical trials that did not confirm the prognostic effect [29–31]. One reason is that baseline S_vO_2 may be high due to EO_2 failure. However, there were other reasons for high baseline S_vO_2 in those trials than in previous trials; more specifically, patients were less sick and S_vO_2 was measured after initial volume treatment. Therefore, although the current recommendation for the use of S_vO_2 for goal-directed therapy (GDT) is not as strong as before, it is still suggested in patients with low S_vO_2 [1, 6].

Marker of incoming distributive shock (uncoupling)

A sudden unexplained elevation in S_vO_2 may imply the development of extraction (i.e., EO_2) failure and microcirculation damage (e.g., systemic inflammatory response or septic shock) [14, 32].

Marker of catheter wedging

When using a PAC equipped with an optic sensor (described above), high S_vO_2 indicates wedging, either unintentionally when the catheter is placed too distally, or appropriate wedging during the measurement of pulmonary capillary wedge pressure [5].

Not a marker of local hypoxia

S_vO_2 is not a sensitive marker of local hypoxia (e.g., acute limb ischemia). In these situations, S_vO_2 will be normal due to the majority of blood with normal S_vO_2 originating from other organs [6].

Near-infrared spectroscopy oximetry

Near-infrared spectroscopy (NIRS) oximetry is a non-invasive method that uses self-adhesive patches equipped with sensors (light emitter and sensors of reflected light are spaced several centimeters from one another) placed on the skin. The light penetrates several centimeters into the tissue and, using several algorithms, provides information regarding the status of oxygenation of HGB in the microcirculation (i.e., mixture of arterioles, capillaries, and venules (peripheral saturation, rSO_2) 3–4 cm under the skin. Because the majority of blood is pooled in the veins, the value is driven, in large part, by venous saturation. Therefore, NIRS oximetry behaves in a manner similar to S_vO_2 (i.e., reflects CO) and is falsely high in conditions with O_2 extraction failure (e.g., sepsis). Hypoperfusion is obvious when $rSO_2 < 50\%$ or if there is a drop $> 20\%$ from baseline. It has been shown that NIRS oximetry values correlate with CO in cardiogenic shock. Currently, this method is increasingly used for non-invasive hemodynamic monitoring [33–36].

Lactate

Physiological principles


The glucose molecule is metabolized to pyruvate without the need for O_2 , generating 2 ATP molecules and known as anaerobic glycolysis. In the presence of O_2 , pyruvate enters the mitochondria, where pyruvate dehydrogenase (PDH) converts pyruvate into the acetylcoenzyme A, which enters the Krebs cycle followed by oxidative phosphorylation (1 glucose molecule generates 36 ATP molecules). When

available O_2 drops to critical levels, DO_2 pyruvate is metabolized by lactate dehydrogenase into lactate. Therefore, lactate is considered to be a marker of anaerobic metabolism. Aside from the hypoxic explanation, however, there are also non-hypoxic pathways for lactate production not related to hypoperfusion in shock that are either increased production or decreased clearance. Non-hypoxic production occurs in septic shock due to excessive β -adrenergic stimulation of muscle cells by intrinsic mechanisms or by the administration of catecholamines [37, 38]. It leads to excessive glycogenolysis and glycolysis. Increased glycolysis produces an abundance of pyruvate that overwhelms the capacity of PDH, thus leading to lactate production. Another reason is malfunction of PDH and other mitochondrial enzymes of aerobic metabolism induced by septic toxins. The liver and kidneys are responsible for clearance of up to 90% of lactate (lactate is converted back to pyruvate by entering the Krebs cycle or is used for gluconeogenesis in the Cori cycle). In case of their hypoperfusion or enzyme failure, clearance is diminished [14, 39] (Fig. 5).

Measurement

Blood lactate level is routinely measured from blood samples (point-of-care test). Even during the first hours of shock or during decompensation, it is sufficient to measure lactate levels every 1–2 h due to its slower kinetics [6, 28]. There are even systems for continuous invasive monitoring of lactate levels [40].

Fig. 5 Glucose metabolism and the production of lactate



Clinical applications

Marker of anaerobic metabolism (adequacy of CO)

Lactate informs about perfusion indirectly by reflecting anaerobic metabolism [6]. Because it requires switch of metabolism it is late marker of hypoperfusion not as sensitive in detecting early stages of hypoperfusion as S_vO_2 , PCO_2 gap or PCO_2 gap/ $C_{a-v}O_2$. The cut-off value indicating hypoperfusion is > 2 mmol/l. Lactate exhibits a similar biphasic curvilinear shape of dependence on CO like other parameters, except for septic shock, where the normalization occurs slower (Fig. 2, lactate in septic shock, lactate in non-septic state—curve would be similar to PCO_2 curve) [41, 42]. First, it is due to non-hypoxic reasons for lactate elevation and, second, to microvascular uncoupling. The correlation between lactate and CO is, therefore, weaker. Improving CO initially causes a rapid drop in lactate, followed by persistent only slowly decreasing lactate levels despite the already normalized perfusion. Therefore, trying to normalize lactate could lead to harmful over-resuscitation by fluid and inotropes [8]. Normalization of PCO_2 gap and PCO_2 gap/ $C_{a-v}O_2$ ratio (faster reacting markers of anaerobic metabolism) would suggest that perfusion is normalized and lactate level is elevated for other reasons. Lactate/pyruvate ratio was proposed to discriminate non-hypoxic lactate elevation (> 18 indicates anaerobic metabolism) but it is not widely used due to technical difficulties with measuring pyruvate [14].

Prognostic marker and GDT

Lactate is the only parameter to have clear evidence for GDT and is strongly recommended for navigation of treatment by guidelines [6, 28]. Both high value and slow clearance are associated with worse prognosis. Conversely, bringing lactate levels under 2 mmol/l or clearance $> 20\%$ every 2 h in the early stage(s) of septic shock (first 8 h) or $> 50\%$ in the first 6 h is associated with improved outcomes [1, 6, 43, 44].

Marker of distributive shock (uncoupling)

When CO and S_vO_2 are normal, increased lactate level can imply microvascular and cellular failure [1, 41].

Marker of local hypoxia

Lactate levels can be elevated also if local hypoxia occurs (e.g., acute limb ischemia). Global hypoxia can be ruled out based on other perfusion parameters that would be normal [14].

PCO_2 gap (ΔPCO_2 , $P_{v-a}CO_2$)

PCO_2 gap is the difference between venous and arterial partial pressures of CO_2 .

Physiological principles

Unlike O_2 , only 5% of CO_2 is reversibly bound to proteins, mainly HGB (to the amino group creating carbamino HGB). On the other hand, CO_2 is more physically dissolved in blood than O_2 because it is 20 times more soluble, but still comprises only 5% of CO_2 in the blood. The majority (90%) of CO_2 in blood is in the form of bicarbonate: the CO_2 originating from tissues combines with water (H_2O) to form H_2CO_3 . This takes place mainly in erythrocytes catalyzed by carbonic anhydrase (only a minority of CO_2 is created slowly uncatalyzed in plasma). H_2CO_3 dissociates in erythrocytes into HCO_3^- and H^+ . HCO_3^- leaves the erythrocytes via a bicarbonate/chloride exchanger and is dissolved in blood flowing to the lungs, where the reverse reaction occurs (in erythrocytes and the lung endothelium), catalyzed by carbonic anhydrase and bringing H_2O and CO_2 [15]. CO_2 is highly lipophilic and freely diffuses through membranes and is exhaled by the lungs. The CO_2 dissociation curve (relation between PCO_2 and content of CO_2) is curvilinear (unlike O_2 , which is S-shaped); however, in the physiological range, it is near linear, which is why CO_2 content can be substituted by $PCO_2 * k$ (dissociation coefficient).

As mentioned above, PCO_2 gap is the difference between partial pressure of CO_2 in arterial and venous blood. As described for S_vO_2 , the Fick principle can also be applied: CO_2 production (VCO_2) is proportional to a flow through the tissues and arteriovenous concentration difference in CO_2 [45, 46]:

$$VCO_2 = CO \times (C_aCO_2 - C_vCO_2),$$

where C_a and C_vCO_2 represent the arterial and venous concentrations of CO_2 , respectively.

Also mentioned above, concentration can be calculated from partial pressure (PCO_2) as follows:

$$VCO_2 = CO \times k \times (P_vCO_2 - P_aCO_2) = CO \times k \times P_{(v-a)}CO_2$$

and

$$PCO_2 \text{ gap} = \frac{VCO_2}{CO \times k}$$

PCO_2 gap is proportional to CO_2 production (VCO_2) in tissues and inversely related to CO (i.e., flow through the tissues (elimination from tissues) [47]. In normoxemia, aerobic production of CO_2 occurs in the Krebs cycle. In hypoxemia, VCO_2 remains relatively stable because, although aerobic

production of CO_2 decreases, it is partly counterbalanced by increased anaerobic production. In fact, VCO_2 slightly decreases during hypoxia despite anaerobic CO_2 generation; however, for clinical purposes, it can be considered constant. Anaerobic CO_2 production comes from increased production of H^+ buffered by HCO_3^- (further converted to CO_2). The source of H^+ is mainly from ATP hydrolysis, then lactate production (although lactate production does not generate H^+ directly because one H^+ is generated to make pyruvate from glucose, but one H^+ is consumed to make lactate from pyruvate), and other enzymes producing H^+ . In normoxic conditions, H^+ is consumed in oxidative phosphorylation, which is not the case in anaerobic metabolism [14, 39] (Fig. 6).

This explains why PCO_2 gap cannot be used to detect hypoxia and anaerobic metabolism—normal PCO_2 gap does not mean the absence of hypoxia. As mentioned above, because VCO_2 is essentially constant in normoxia and hypoxia, and because the diffusibility through membranes and solubility in blood is very high (not restricting CO_2 elimination from tissues), PCO_2 gap is determined solely by capillary venous outflow (i.e., CO, that clears produced CO_2 [45]:

$$\text{PCO}_2 \text{ gap} \uparrow = \frac{\text{VCO}_2}{\text{CO} \downarrow \times k}$$




Fig. 6 Production of carbon dioxide (CO_2) and its relationship with cardiac output (CO). All produced CO_2 easily diffuses and dissolves in blood. Transport from tissues to the venous blood does not restrict clearance from tissues. All produced CO_2 always gets to the venous blood without accumulation in the tissues, and its concentration in the veins depends only on venous return. Higher CO leads to smaller venous CO_2 concentration and smaller arteriovenous difference.

When DO_2 was lowered beyond critical value in a canine model, either by reducing blood flow using blood with normal SaO_2 , or by preserved blood flow but with low S_aO_2 . The former lead to an increase in PCO_2 gap, whereas the latter did not change PCO_2 gap [48].

Difference between $\text{P}_{\text{cv}}\text{CO}_2$ and $\text{P}_{\text{v}}\text{CO}_2$

The values of PCO_2 gap exhibit the same trends as $\text{S}_{\text{v}}\text{O}_2$ when using mixed venous blood ($\text{P}_{(\text{v-a})}\text{CO}_2$) or central venous blood (ΔPCO_2). Again, similar to the case of $\text{S}_{\text{v}}\text{O}_2$, the use of central venous blood is widely accepted as a surrogate for calculation of PCO_2 gap [46, 49].

Measurement of PCO_2 gap

PCO_2 gap is routinely measured from blood samples (point-of-care test); however, there are some limitations. The blood capacity for CO_2 is increased (dissociation curve is not linear) with low HGB saturation with O_2 (hypoxia, Haldane effect) and acidosis by carrying more CO_2 by HGB. In severe hypoxia and acidosis, CO_2 content can be increased by these factors at a given PCO_2 and, therefore, calculation of CO_2 gap from pCO_2 can be imprecise [14].

Lower CO leads to slower flow through capillaries and the entire CO_2 production is dissolved in smaller venous blood volume, known as the “stagnation phenomenon”. This is why there is higher amount of CO_2 dissolved in venous blood and higher arteriovenous difference. The same applies to reduced capillary net (despite normal CO) when CO_2 from areas with damaged net is drained by remaining capillaries leading inevitably to high CO_2 concentration. HCO_3^- , bicarbonate

Clinical applications

Marker of venous return (adequacy of CO)

Venous content of CO_2 and PCO_2 gap depends, in fact, only on microvasculatory venous return (Fig. 6) and PCO_2 gap reflects venous return from the capillary bed and the adequacy of the microcirculation [14].

In the state of coupling macro- and microcirculation, it indirectly reflects CO and has similar biphasic curvilinear shape of dependence on CO similar to other parameters [50] (Fig. 2). It does not have as robust evidence as other parameters on GDT; however, guidelines have recommended the use of PCO_2 gap to help assess the adequacy of CO as well as to guide therapy [1]. In normal conditions (normal CO and homogenous healthy capillary bed), all CO_2 production is rapidly washed out, and venoarterial PCO_2 gradient is minimal. PCO_2 gap > 6 mmHg (0.8 kPa) is the cut-off value that implies inadequate CO; in that case, the therapeutic option could be to increase CO with the aim of normalizing PCO_2 gap. On the other hand, in shock with persistent elevation of lactate levels (see below), normalized PCO_2 gap will indicate the risk for potentially harmful over-resuscitation using fluid and inotropes. The variation of CO_2 occurs faster than lactate changes; therefore, it is more sensitive marker to hemodynamic changes [14].

In contrast, in the uncoupling state (distributive shock), there is a weak correlation between PCO_2 gap and CO (similar to S_{vO_2}) because of decreased functional capillary density, with areas with good and poor perfusion (Fig. 6); this can lead to elevation of venous CO_2 content and PCO_2 gap despite normal or high CO. In such situations, some patients may benefit from an increase in CO to supranormal value if signs of hypoperfusion persist [51].

Prognostic marker

Persistent elevation of PCO_2 gap in patients with septic shock has been shown to be associated with worse prognosis [52].

Not a marker of hypoxia

As mentioned above, PCO_2 gap does not indicate the metabolic impact of hypoperfusion—it does not reflect hypoxia [47].

$\text{C}_{\text{v-a}}\text{CO}_2/\text{C}_{\text{a-v}}\text{O}_2$ ratio

Physiological principles

This ratio is derived from the RQ, which reflects the ratio of moles of CO_2 generated per mole of O_2 ; it can be directly measured by calorimetry and expressed by the equation:

$$\text{RQ} = \frac{\text{VCO}_2}{\text{VO}_2}$$

However, it can be also calculated based on the Fick principle:

$$\text{RQ} = \frac{\text{CO} \times (\text{C}_{\text{v}}\text{CO}_2 - \text{C}_{\text{a}}\text{CO}_2)}{\text{CO} \times (\text{C}_{\text{a}}\text{O}_2 - \text{C}_{\text{v}}\text{O}_2)} = \frac{\text{C}_{\text{v-a}}\text{CO}_2}{\text{C}_{\text{a-v}}\text{O}_2}$$

Using the partial pressure of CO_2 , it can be obtained a surrogate of RQ:

$$\text{RQ} = \frac{\text{P}_{\text{v-a}}\text{CO}_2}{\text{C}_{\text{a-v}}\text{O}_2} = \frac{\text{PCO}_2 \text{ gap}}{\text{C}_{\text{a-v}}\text{O}_2}$$

In aerobic metabolism, one O_2 molecule leads approximately to the production of one CO_2 molecule, and $\text{RQ} = 1$. In hypoperfusion leading to anaerobic metabolism, there is a decline in both VO_2 and VCO_2 ; however, this decline is asymmetric. As mentioned above, VCO_2 decreases only slightly due to counterbalancing of the aerobic production decrease by an increase in anaerobic production:




Fig. 7 Relationship between carbon dioxide output (VCO_2) and oxygen consumption (VO_2) (the respiratory quotient) under aerobic and anaerobic metabolism. DO_2 , oxygen delivery

Table 2 Summary of the clinical use of selected biochemical parameters of global oxygen (O₂) metabolism for the assessment of microcirculation and tissue perfusion

Parameter	Clinical application as a marker	Cut-off value(s)
S _v O ₂	Hypoxia	< 65%
	Extraction O ₂ from hemoglobin	> 80%
	Microcirculation and cell failure (high S _v O ₂)	
Lactate	Hypoxia	> 2 mmol/l
	Anaerobic metabolism	
	Strongest data for GDT	
	Also detects local hypoxia	
PCO ₂ gap	Venous return—perfusion	> 0.8 kPa (> 6 mmHg)
PCO ₂ gap/C _{a-v} O ₂	Hypoxia	> 1.4
	Anaerobic metabolism	

C_{a-v}O₂, central venous-to-arterial CO₂ difference; GDT, goal-directed therapy; PCO₂ gap, central venous–arterial carbon dioxide difference; S_vO₂, mixed venous oxygen saturation

$$RQ \uparrow = \frac{VCO_2 \downarrow}{VO_2 \downarrow\downarrow}$$

Therefore RQ > 1 implies a switch to anaerobic metabolism (Fig. 7).

The C_{v-a}CO₂/C_{a-v}O₂ ratio appears to correspond with lactatemia and RQ measured by calorimetry; however, according to some trials, the surrogate PCO₂ gap/C_{a-v}O₂ ratio may be imprecise due to the Haldane effect [14, 45].

Clinical applications

Marker of anaerobic metabolism (adequacy of CO)

A PCO₂ gap/C_{a-v}O₂ > 1.4 implies anaerobic metabolism. Its advantage compared to lactate is an earlier reaction [45]. The elevation of both PCO₂ gap/C_{a-v}O₂ and lactate strongly indicate ongoing anaerobic metabolism. If PCO₂ gap/C_{a-v}O₂




Fig. 8 Algorithm for the use of parameters of global oxygen metabolism (adapted from Mallat et al. [45] and Vallet et al. [56]). C_{a-v}O₂, central venous-to-arterial oxygen difference; CO, cardiac output; DO₂, oxygen delivery; HGB, hemoglobin; PCO₂ gap, central venous–

arterial carbon dioxide difference; S_aO₂, oxygen saturation; S_vO₂, mixed venous oxygen saturation; VO₂, oxygen consumption; ↑, increase; ↓, decrease

is elevated but lactate levels are normal, it can suggest the onset of anaerobic metabolism (early stage[s] of shock). If $\text{PCO}_2 \text{ gap}/\text{C}_{a-v}\text{O}_2$ is normal but elevated lactate levels persist, it suggests resolution of aerobic metabolism with persistent lactate elevation from non-hypoxic causes (see above), and over-resuscitation with fluids and inotropes is discouraged [14, 53].

Prognostic marker

It has been shown that patients with septic shock and increased $\text{PCO}_2 \text{ gap}/\text{C}_{a-v}\text{O}_2$ have a worse prognosis [54]. In contrast to lactate levels, evidence supporting $\text{PCO}_2 \text{ gap}/\text{C}_{a-v}\text{O}_2$ for GDT is lacking.

Marker of distributive shock (uncoupling)

When CO and S_vO_2 are high, increased lactate and $\text{PCO}_2 \text{ gap}/\text{C}_{a-v}\text{O}_2$ can imply microvascular and cellular failure [55].

Algorithm for assessment and monitoring of microcirculation and tissue perfusion

The abovementioned biochemical parameters of global O_2 metabolism are used as clinical markers of different aspects of the microcirculation and tissue perfusion status (Table 2). The precise analysis and accurate interpretation of the measured values enable the recognition of the specific cause of tissue hypoperfusion and optimize the therapeutic intervention. We propose an algorithm for the evaluation of tissue perfusion and microcirculation status and related therapeutic consequences that are based on the findings (Fig. 8).

Conclusion

The assessment and monitoring of the microcirculation and tissue perfusion is extremely important in conditions involving circulatory shock. Whereas parameters of the macrocirculation, such as blood pressure or CO, are relatively easily available and are amenable to simple interpretation, the situation at the microcirculatory level is significantly more complex. Moreover, there is often only very limited correlation between the findings at the macrocirculation and microcirculation levels, and therapies directed at simply normalizing the macrocirculation without the knowledge of the status of the microcirculation

can be even harmful. Currently, the available methods for evaluating the microcirculation are very limited. In recent years, biochemical markers of global O_2 metabolism have become routinely used in the assessment of tissue perfusion. However, the interpretation of these values must be based on knowledge of physiological principles and in the context of other findings. Nevertheless, there is mounting evidence that accurate assessment and monitoring of tissue perfusion using parameters of global O_2 metabolism is essential for the selection of the most appropriate therapeutic strategy and may improve therapeutic outcomes in patients with critical circulatory conditions.

Acknowledgements The work was supported by an Institutional grant MH CZ—DRO (Nemocnice Na Homolce—NNH, 00023884), IG150501.

Author contributions MJ wrote the first draft of the manuscript. PO critically reviewed and revised the manuscript for important intellectual content. Both authors approved the final version for publication.

Data availability Not applicable.

Code availability Not applicable.

Compliance with ethical standards

Conflict of interest The authors declare that they have no competing interests.

Ethical approval Not applicable.

Consent to participate Not applicable.

Consent for publication Not applicable.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

References

1. Cecconi M, De Backer D, Antonelli M, Beale R, Bakker J, Hofer C, Jaeschke R, Mebazaa A, Pinsky MR, Teboul JL, Vincent JL, Rhodes A (2014) Consensus on circulatory shock and hemodynamic monitoring. Task force of the European Society of Intensive Care Medicine. *Intensive Care Med* 40:1795–1815. <https://doi.org/10.1007/s00134-014-3525-z>

2. Baran DA, Grines CL, Bailey S, Burkhoff D, Hall SA, Henry TD, Hollenberg SM, Kapur NK, O'Neill W, Ornato JP, Stelling K, Thiele H, van Diepen S, Naidu SS (2019) SCAI clinical expert consensus statement on the classification of cardiogenic shock: this document was endorsed by the American College of Cardiology (ACC), the American Heart Association (AHA), the Society of Critical Care Medicine (SCCM), and the Society of Thoracic Surgeons (STS) in April 2019. *Catheter Cardiovasc Interv* 94:29–37. <https://doi.org/10.1002/ccd.28329>
3. Thiele H, Ohman EM, de Waha-Thiele S, Zeymer U, Desch S (2019) Management of cardiogenic shock complicating myocardial infarction: an update 2019. *Eur Heart J* 40:2671–2683. <https://doi.org/10.1093/eurheartj/ehz363>
4. Saugel B, Vincent JL (2018) Cardiac output monitoring: how to choose the optimal method for the individual patient. *Curr Opin Crit Care* 24:165–172. <https://doi.org/10.1097/MCC.0000000000000492>
5. Ragosta M (2018) Textbook of clinical hemodynamics. Elsevier, Philadelphia
6. Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, Kumar A, Sevransky JE, Sprung CL, Nunnally ME, Rochwerf B, Rubenfeld GD, Angus DC, Annane D, Beale RJ, Bellinhan GJ, Bernard GR, Chiche JD, Coopersmith C, De Backer DP, French CJ, Fujishima S, Gerlach H, Hidalgo JL, Hollenberg SM, Jones AE, Karnad DR, Kleinpell RM, Koh Y, Lisboa TC, Machado FR, Marini JJ, Marshall JC, Mazuski JE, McIntyre LA, McLean AS, Mehta S, Moreno RP, Myburgh J, Navalesi P, Nishida O, Osborn TM, Perner A, Plunkett CM, Ranieri M, Schorr CA, Seckel MA, Seymour CW, Shieh L, Shukri KA, Simpson SQ, Singer M, Thompson BT, Townsend SR, Van der Poll T, Vincent JL, Wiersinga WJ, Zimmerman JL, Dellinger RP (2017) Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock: 2016. *Intensive Care Med* 43:304–377. <https://doi.org/10.1007/s00134-017-4683-6>
7. Hayes MA, Timmins AC, Yau EH, Palazzo M, Hinds CJ, Watson D (1994) Elevation of systemic oxygen delivery in the treatment of critically ill patients. *N Engl J Med* 330(24):1717–1722. <https://doi.org/10.1056/NEJM199406163302404>
8. Vincent JL, Bihari DJ (1994) Elevation of systemic oxygen delivery in the treatment of critically ill patients. *N Engl J Med* 331:1160–1161. <https://doi.org/10.1056/NEJM199410273311715>
9. Elbers P, Rodrigus T, Nossent E, Malbrain ML, Vonk-Noordegraaf A (2015) Fluid therapy in critically ill patients: perspectives from the right heart. *Anaesthesiol Intensive Ther* 47:s38–s43. <https://doi.org/10.5603/AIT.a2015.0080>
10. Eriksson S, Nilsson J, Stureson C (2014) Non-invasive imaging of microcirculation: a technology review. *Med Devices (Auckl)* 7:445–452. <https://doi.org/10.2147/MDER.S51426>
11. Ait-Oufella H, Lemoine S, Boelle PY, Galbois A, Baudel JL, Lemant J, Joffre J, Margetis D, Guidet B, Maury E, Offenstadt G (2011) Mottling score predicts survival in septic shock. *Intensive Care Med* 37:801–807. <https://doi.org/10.1007/s00134-011-2163-y>
12. Angele MK, Pratschke S, Hubbard WJ, Chaudry IH (2014) Gender differences in sepsis: cardiovascular and immunological aspects. *Virulence* 5:12–19. <https://doi.org/10.4161/viru.26982>
13. Khirfan G, Almoushref A, Naal T, Abuhalmeh B, Dweik RA, Heresi GA, Tonelli AR (2020) Mixed venous oxygen saturation is a better prognosticator than cardiac index in pulmonary arterial hypertension. *Chest*. <https://doi.org/10.1016/j.chest.2020.06.053>
14. Pinsky MR, Teboul JL, Vincent JL (2019) Hemodynamic monitoring. Springer, New York
15. Pearse R, Hodes A (2005) Mixed and central venous oxygen saturation. In: Vincent JL (ed) Yearbook of intensive care and emergency medicine 2005. Springer, New York
16. Bryan-Brown CW (1975) Tissue blood flow and oxygen transport in critically ill patients. *Crit Care Med* 3:103–108. <https://doi.org/10.1097/00003246-197505000-00005>
17. Ince C, Sinaasappel M (1999) Microcirculatory oxygenation and shunting in sepsis and shock. *Crit Care Med* 27:1369–1377. <https://doi.org/10.1097/00003246-199907000-00031>
18. Fink MP (2002) Cytopathic hypoxia. Is oxygen use impaired in sepsis as a result of an acquired intrinsic derangement in cellular respiration? *Crit Care Clin* 18:165–175. [https://doi.org/10.1016/S0749-0704\(03\)00071-x](https://doi.org/10.1016/S0749-0704(03)00071-x)
19. De Backer D, Creteur J, Dubois MJ, Sakr Y, Koch M, Verdant C, Vincent JL (2006) The effects of dobutamine on microcirculatory alterations in patients with septic shock are independent of its systemic effects. *Crit Care Med* 34:403–408. <https://doi.org/10.1097/01.ccm.0000198107.61493.5a>
20. Lough M (2015) Hemodynamic monitoring, evolving technologies and clinical practice. Elsevier, St. Louis
21. Caille V, Squara P (2006) Oxygen uptake-to-delivery relationship: a way to assess adequate flow. *Crit Care* 10(Suppl 3):S4. <https://doi.org/10.1186/cc4831>
22. Reinhart K, Rudolph T, Bredle DL, Hannemann L, Cain SM (1989) Comparison of central-venous to mixed-venous oxygen saturation during changes in oxygen supply/demand. *Chest* 95:1216–1221. <https://doi.org/10.1378/chest.95.6.1216>
23. Ramakrishna MN, Hegde DP, Kumaraswamy GN, Gupta R, Girish TN (2006) Correlation of mixed venous and central venous oxygen saturation and its relation to cardiac index. *Indian J Crit Care Med* 10:230–234
24. Cavalieri F, Zamparelli R, Martinelli L, Scapigliati A, De Paulis S, Caricato A, Gargaruti R, Cina A (2014) Blood from the right atrium may provide closer estimates of mixed venous saturation than blood from the superior vena cava. A pilot study. *Minerva Anesthesiol* 80:11–18
25. Li L, Subramaniam B, Aguirre AD, Andrawes MN, Tearney GJ (2016) In-vivo continuous monitoring of mixed venous oxygen saturation by photoacoustic transesophageal echocardiography. *Photonic therapeutics and diagnostics XII*
26. Liakopoulos OJ, Ho JK, Yezbick A, Sanchez E, Naddell C, Buckberg GD, Crowley R, Mahajan A (2007) An experimental and clinical evaluation of a novel central venous catheter with integrated oximetry for pediatric patients undergoing cardiac surgery. *Anesth Analg* 105(6):1598–1604. <https://doi.org/10.1213/01.ane.0000287657.08434.dc>
27. Levy B, Bastien O, Karim B, Cariou A, Chouihed T, Combes A, Mebazaa A, Megarbane B, Plaisance P, Ouattara A, Spaulding C, Teboul JL, Vanhuysse F, Boulain T, Kuteifan K (2015) Experts' recommendations for the management of adult patients with cardiogenic shock. *Ann Intensive Care* 5:52. <https://doi.org/10.1186/s13613-015-0052-1>
28. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, Sevransky JE, Sprung CL, Douglas IS, Jaeschke R, Osborn TM, Nunnally ME, Townsend SR, Reinhart K, Kleinpell RM, Angus DC, Deutschman CS, Machado FR, Rubenfeld GD, Webb S, Beale RJ, Vincent JL, Moreno R, Surviving Sepsis Campaign Guidelines Committee including The Pediatric S (2013) Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. *Intensive Care Med* 39:165–228. <https://doi.org/10.1007/s00134-012-2769-8>
29. Investigators A, Group ACT, Peake SL, Delaney A, Bailey M, Bellomo R, Cameron PA, Cooper DJ, Higgins AM, Holdgate

- A, Howe BD, Webb SA, Williams P (2014) Goal-directed resuscitation for patients with early septic shock. *N Engl J Med* 371:1496–506. <https://doi.org/10.1056/NEJMoa1404380>
30. Pro CI, Yealy DM, Kellum JA, Huang DT, Barnato AE, Weissfeld LA, Pike F, Terndrup T, Wang HE, Hou PC, LoVecchio F, Filbin MR, Shapiro NI, Angus DC (2014) A randomized trial of protocol-based care for early septic shock. *N Engl J Med* 370:1683–1693. <https://doi.org/10.1056/NEJMoa1401602>
 31. Mouncey PR, Osborn TM, Power GS, Harrison DA, Sadique MZ, Grieve RD, Jahan R, Harvey SE, Bell D, Bion JF, Coats TJ, Singer M, Young JD, Rowan KM, Pro MTI (2015) Trial of early, goal-directed resuscitation for septic shock. *N Engl J Med* 372:1301–1311. <https://doi.org/10.1056/NEJMoa1500896>
 32. Textoris J, Fouche L, Wiramus S, Antonini F, Tho S, Martin C, Leone M (2011) High central venous oxygen saturation in the latter stages of septic shock is associated with increased mortality. *Crit Care* 15:R176. <https://doi.org/10.1186/cc10325>
 33. Scheeren TW, Schober P, Schwarte LA (2012) Monitoring tissue oxygenation by near infrared spectroscopy (NIRS): background and current applications. *J Clin Monit Comput* 26:279–287. <https://doi.org/10.1007/s10877-012-9348-y>
 34. Murkin JM, Arango M (2009) Near-infrared spectroscopy as an index of brain and tissue oxygenation. *Br J Anaesth* 103(Suppl 1):i3–i13. <https://doi.org/10.1093/bja/aep299>
 35. Mozina H, Podbregar M (2011) Near-infrared spectroscopy for evaluation of global and skeletal muscle tissue oxygenation. *World J Cardiol* 3:377–382. <https://doi.org/10.4330/wjc.v3.i12.377>
 36. Ostadal P, Kruger A, Vondrakova D, Janotka M, Psotova H, Neuzil P (2014) Noninvasive assessment of hemodynamic variables using near-infrared spectroscopy in patients experiencing cardiogenic shock and individuals undergoing venoarterial extracorporeal membrane oxygenation. *J Crit Care* 29(690):e11–e15. <https://doi.org/10.1016/j.jcrc.2014.02.003>
 37. James JH, Fang CH, Schrantz SJ, Hasselgren PO, Paul RJ, Fischer JE (1996) Linkage of aerobic glycolysis to sodium-potassium transport in rat skeletal muscle. Implications for increased muscle lactate production in sepsis. *J Clin Invest* 98:2388–2397. <https://doi.org/10.1172/JCI119052>
 38. Levy B, Desebbe O, Montemont C, Gibot S (2008) Increased aerobic glycolysis through beta2 stimulation is a common mechanism involved in lactate formation during shock states. *Shock* 30:417–421. <https://doi.org/10.1097/SHK.0b013e318167378f>
 39. Suetrong B, Walley KR (2016) Lactic acidosis in sepsis: it's not all anaerobic: implications for diagnosis and management. *Chest* 149:252–261. <https://doi.org/10.1378/chest.15-1703>
 40. Chavez J, Glaser S, Krom Z (2020) Continuous lactate measurement devices and implications for critical care: a literature review. *Crit Care Nurs Q* 43:269–273. <https://doi.org/10.1097/CNQ.0000000000000311>
 41. Bakker J (2016) Lactate levels and hemodynamic coherence in acute circulatory failure. *Best Pract Res Clin Anaesthesiol* 30:523–530. <https://doi.org/10.1016/j.bpa.2016.11.001>
 42. Hernandez G, Luengo C, Bruhn A, Kattan E, Friedman G, Ospina-Tascon GA, Fuentealba A, Castro R, Regueira T, Romero C, Ince C, Bakker J (2014) When to stop septic shock resuscitation: clues from a dynamic perfusion monitoring. *Ann Intensive Care* 4:30. <https://doi.org/10.1186/s13613-014-0030-z>
 43. Puskarich MA, Trzeciak S, Shapiro NI, Arnold RC, Heffner AC, Kline JA, Jones AE, Emergency Medicine Shock Research N (2012) Prognostic value and agreement of achieving lactate clearance or central venous oxygen saturation goals during early sepsis resuscitation. *Acad Emerg Med* 19:252–8. <https://doi.org/10.1111/j.1553-2712.2012.01292.x>
 44. Hernandez G, Ospina-Tascon GA, Damiani LP, Estenssoro E, Dubin A, Hurtado J, Friedman G, Castro R, Alegria L, Teboul JL, Cecconi M, Ferri G, Jibaja M, Pairumani R, Fernandez P, Barahona D, Granda-Luna V, Cavalcanti AB, Bakker J, The ASI, the Latin America Intensive Care N, Hernandez G, Ospina-Tascon G, Petri Damiani L, Estenssoro E, Dubin A, Hurtado J, Friedman G, Castro R, Alegria L, Teboul JL, Cecconi M, Cecconi M, Ferri G, Jibaja M, Pairumani R, Fernandez P, Barahona D, Cavalcanti AB, Bakker J, Hernandez G, Alegria L, Ferri G, Rodriguez N, Holger P, Soto N, Pozo M, Bakker J, Cook D, Vincent JL, Rhodes A, Kavanagh BP, Dellinger P, Rietdijk W, Carpio D, Pavez N, Henriquez E, Bravo S, Valenzuela ED, Vera M, Dreysse J, Oviedo V, Cid MA, Larroulet M, Petruska E, Sarabia C, Gallardo D, Sanchez JE, Gonzalez H, Arancibia JM, Munoz A, Ramirez G, Aravena F, Aquevedo A, Zambrano F, Bozinovic M, Valle F, Ramirez M, Rossel V, Munoz P, Ceballos C, Esveile C, Carmona C, Candia E, Mendoza D, Sanchez A, Ponce D, Ponce D, Lastra J, Nahuelpan B, Fasce F, Luengo C, Medel N, Cortes C, Campassi L, Rubatto P, Horna N, Furche M, Pendino JC, Bettini L, Lovesio C, Gonzalez MC, Rodriguez J, Canales H, Caminos F, Galletti C, Minoldo E, Aramburu MJ, Olmos D, Nin N, Tenzi J, Quiroga C, Lacuesta P, Gaudin A, Pais R, Silvestre A, Olivera G, Rieppi G, Berrutti D, Ochoa M, Cobos P, Vintimilla F, Ramirez V, Tobar M, Garcia F, Picoita F, Remache N, Granda V, Paredes F, Barzallo E, Garces P, Guerrero F, Salazar S, Torres G, Tana C, Calahorrano J, Solis F, Torres P, Herrera L, Ornes A, Perez V, Delgado G, Lopez A, Espinosa E, Moreira J, Salcedo B, Villacres I, Suing J, Lopez M, Gomez L, Toctaquiza G, Cadena Zapata M, Orazabal MA, Pardo Espejo R, Jimenez J, Calderon A, Paredes G, Barberan JL, Moya T, Atehortua H, Sabogal R, Ortiz G, Lara A, Sanchez F, Hernan Portilla A, Davila H, Mora JA, Calderon LE, Alvarez I, Escobar E, Bejarano A, Bustamante LA, Aldana JL (2019) Effect of a resuscitation strategy targeting peripheral perfusion status vs serum lactate levels on 28-day mortality among patients with septic shock: the ANDROMEDA-SHOCK randomized clinical trial. *JAMA* 321:654–664. <https://doi.org/10.1001/jama.2019.0071>
 45. Mallat J, Lemyze M, Meddour M, Pepy F, Gasan G, Barrailler S, Durville E, Temime J, Vangrunderbeeck N, Tronchon L, Vallet B, Thevenin D (2016) Ratios of central venous-to-arterial carbon dioxide content or tension to arteriovenous oxygen content are better markers of global anaerobic metabolism than lactate in septic shock patients. *Ann Intensive Care* 6:10. <https://doi.org/10.1186/s13613-016-0110-3>
 46. van Beest PA, Lont MC, Holman ND, Loeff B, Kuiper MA, Boerma EC (2013) Central venous-arterial pCO₂ difference as a tool in resuscitation of septic patients. *Intensive Care Med* 39:1034–1039. <https://doi.org/10.1007/s00134-013-2888-x>
 47. Mallat J, Lemyze M, Tronchon L, Vallet B, Thevenin D (2016) Use of venous-to-arterial carbon dioxide tension difference to guide resuscitation therapy in septic shock. *World J Crit Care Med* 5:47–56. <https://doi.org/10.5492/wjccm.v5.i1.47>
 48. Vallet B, Teboul JL, Cain S, Curtis S (2000) Venoarterial CO₂ difference during regional ischemic or hypoxic hypoxia. *J Appl Physiol* (1985) 89:1317–1321. <https://doi.org/10.1152/jappl.2000.89.4.1317>
 49. Cuschieri J, Rivers EP, Donnino MW, Katilius M, Jacobsen G, Nguyen HB, Pamukov N, Horst HM (2005) Central venous-arterial carbon dioxide difference as an indicator of cardiac index. *Intensive Care Med* 31:818–822. <https://doi.org/10.1007/s00134-005-2602-8>
 50. Creteur J, De Backer D, Sakr Y, Koch M, Vincent JL (2006) Sublingual capnometry tracks microcirculatory changes in septic patients. *Intensive Care Med* 32:516–523. <https://doi.org/10.1007/s00134-006-0070-4>
 51. Shoemaker WC, Appel PL, Kram HB (1992) Role of oxygen debt in the development of organ failure sepsis, and death in high-risk

- surgical patients. *Chest* 102:208–215. <https://doi.org/10.1378/chest.102.1.208>
52. Gattinoni L, Brazzi L, Pelosi P, Latini R, Tognoni G, Pesenti A, Fumagalli R (1995) A trial of goal-oriented hemodynamic therapy in critically ill patients. SvO₂ Collaborative Group. *N Engl J Med* 333:1025–1032. <https://doi.org/10.1056/NEJM199510193331601>
53. He H, Long Y, Liu D, Wang X, Tang B (2017) The Prognostic value of central venous-to-arterial CO₂ difference/arterial-central venous O₂ difference ratio in septic shock patients with central venous O₂ saturation ≥ 80 . *Shock* 48:551–557. <https://doi.org/10.1097/SHK.0000000000000893>
54. He HW, Liu DW, Long Y, Wang XT (2016) High central venous-to-arterial CO₂ difference/arterial-central venous O₂ difference ratio is associated with poor lactate clearance in septic patients after resuscitation. *J Crit Care* 31:76–81. <https://doi.org/10.1016/j.jcrc.2015.10.017>
55. Monnet X, Julien F, Ait-Hamou N, Lequoy M, Gosset C, Jozwiak M, Persichini R, Anguel N, Richard C, Teboul JL (2013) Lactate and venoarterial carbon dioxide difference/arterial-venous oxygen difference ratio, but not central venous oxygen saturation, predict increase in oxygen consumption in fluid responders. *Crit Care Med* 41:1412–1420. <https://doi.org/10.1097/CCM.0b013e318275cece>
56. Vallet B, Pinsky MR, Cecconi M (2013) Resuscitation of patients with septic shock: please “mind the gap”! *Intensive Care Med* 39:1653–1655. <https://doi.org/10.1007/s00134-013-2998-5>

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.